Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt-Koyanagi-Harada Disease.

Pharmaceuticals (Basel) · 2025 · PMC12736142 · PMID 41471337

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Changes in other secondary outcomes did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.